Abstract
This Pathobiology issue tries to better define the complex phenomenon of intratumor heterogeneity (ITH), mostly from a practical point of view. This topic has been chosen because ITH is a central issue in tumor development and has to be investigated directly in patient tissue and immediately applied in the treatment of the presenting patient. Different types of ITH should be considered: clonal genetic and epigenetic evolution, morphological heterogeneity, and tumor sampling, heterogeneity resulting from microenvironmental autocrine and paracrine interaction, and stochastic plasticity related to different functional cell efficiencies. For a higher level of reproducibility in clinical research and diagnostics, it is necessary to establish standardized analytical methods, including microdissection. In situ techniques can be pivotal to explore tumor microenvironment and can be improved with associated digital analysis. Liquid biopsies for plasma DNA analysis are at present the best method to study recurrent tumors with treatment adaptation, and widespread clinical use could be beneficial. The different types of tumor genomic instabilities could have pragmatic applications to rank ITH for clinical applications: treatment approaches differ in patients with a high nucleotide mutation rate and patients with high copy number alterations.
References
1.
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
2.
Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
3.
Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-49.
4.
Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209.
5.
Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-550.
6.
Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-322.
7.
Cancer Genome Atlas Research Network: The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011-1025.
8.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA: Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
9.
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L: Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-339.
10.
Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R: On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther 2015;14:1488-1494.
11.
Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl AS, Davis C, Lau CY, Pandya C, Shah H, Kasai Y, Powell J, Micchelli M, Castellanos R, Zhang Z, Linderman M, Kinoshita Y, Zweig M, Raustad K, Cheung K, Castillo D, Wooten M, Bourzgui I, Newman LC, Deikus G, Mathew B, Zhu J, Glicksberg BS, Moe AS, Liao J, Edelmann L, Dudley JT, Maki RG, Kasarskis A, Holcombe RF, Mahajan M, Hao K, Reva B, Longtine J, Starcevic D, Sebra R, Donovan MJ, Li S, Schadt EE, Chen R: Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med 2016;8:62.
12.
Mengersen K, McGree JM, Schmid CH: Statistical analysis of N-of-1 trials; in Nikles J, Mitchell G (eds): The Essential Guide to N- of-1 Trials in Health. Dordrecht, Springer Netherlands, 2015, pp 135-153.
13.
Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, Mudry P, Kovacs G, Kiss C, Norga K, Konstantinov D, Andre N, Slavc I, van Den Berg H, Kolenova A, Kren L, Tuma J, Skotakova J, Sterba J: Future paradigms for precision oncology. Oncotarget 2016;7:46813-46831.
14.
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr: Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-990.
15.
Parsons HA, Beaver JA, Park BH: Circulating plasma tumor DNA. Adv Exp Med Biol 2016;882:259-276.
16.
Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sanchez G, Sarno F, Prieto SH, Perea S, Lopez-Casas PP, Lopez-Rios F, Hidalgo M: Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget 2017;8:35289-35300.
17.
Christensen E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, van der Keur K, van Kessel K, Zwarthoff E, Agerbaek M, Orntoft TF, Jensen JB, Dyrskjot L: Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol 2017;71:961-969.
18.
Vilar E, Tabernero J: Cancer: pinprick diagnostics. Nature 2012;486:482-483.
19.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-536.
20.
Burrell RA, Swanton C: Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014;8:1095-1111.
21.
Stanta G, Jahn SW, Bonin S, Hoefler G: Tumour heterogeneity: principles and practical consequences. Virchows Arch 2016;469:371-384.
22.
Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T, McCormack R: Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-1353.
23.
Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, Milenkova T: First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62.
24.
Fenizia F, De Luca A, Pasquale R, Sacco A, Forgione L, Lambiase M, Iannaccone A, Chicchinelli N, Franco R, Rossi A, Morabito A, Rocco G, Piccirillo MC, Normanno N: EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol 2015;11:1611-1623.
25.
Wang J, Song Y: Single cell sequencing: a distinct new field. Clin Transl Med 2017;6:10.
26.
Unreliable research - trouble at the lab: scientists like to think of science as self-correcting. To an alarming degree, it is not. Economist 2013;8858:26-28, 30.
27.
Stanta G: Tissue heterogeneity as a pre-analytical source of variability. Recent Results Cancer Res 2015;199:35-43.
28.
Hlubek F, Brabletz T, Budczies J, Pfeiffer S, Jung A, Kirchner T: Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int J Cancer 2007;121:1941-1948.
29.
Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-334.
30.
Gomez D, Shankman LS, Nguyen AT, Owens GK: Detection of histone modifications at specific gene loci in single cells in histological sections. Nat Methods 2013;10:171-177.
31.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.
32.
Russnes HG, Navin N, Hicks J, Borresen-Dale AL: Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011;121:3810-3818.
33.
Gainor JF, Shaw AT: Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987-3996.
34.
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-726.
35.
Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, Navin NE: Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:155-160.
36.
Alamgeer M, Ganju V, Watkins DN: Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol 2013;13:394-401.
37.
Bardelli A: Precision medicine for colorectal cancer. Precision Medicine for Cancer; March 1-4, 2015, Luxembourg.
38.
Tang J, Fang F, Miller DF, Pilrose JM, Matei D, Huang TH, Nephew KP: Global DNA methylation profiling technologies and the ovarian cancer methylome. Methods Mol Biol 2015;1238:653-675.
39.
Mohn F, Weber M, Schubeler D, Roloff TC: Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol 2009;507:55-64.
40.
Berbegall AP, Villamón E, Navarro S, Noguera R: Multiplex ligation-dependent probe amplification (MLPA); in Stanta G (ed): Guidelines for Molecular Analysis in Archive Tissues. Berlin, Springer, 2011, pp 215-224.
41.
Ragusa M, Barbagallo C, Statello L, Condorelli AG, Battaglia R, Tamburello L, Barbagallo D, Di Pietro C, Purrello M: Non-coding landscapes of colorectal cancer. World J Gastroenterol 2015;21:11709-11739.
42.
Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K: Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 2014;514:54-58.
43.
Kleppe M, Levine RL: Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med 2014;20:342-344.
44.
Schito L, Rey S, Tafani M, Zhang H, Wong CC, Russo A, Russo MA, Semenza GL: Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA 2012;109:E2707-E2716.
45.
Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-237.
46.
Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105:93-103.
47.
Chien J, Kuang R, Landen C, Shridhar V: Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol 2013;3:251.
48.
Espinosa I, Catasus L, D'Angelo E, Mozos A, Pedrola N, Bertolo C, Ferrer I, Zannoni GF, West RB, van de Rijn M, Matias-Guiu X, Prat J: Stromal signatures in endometrioid endometrial carcinomas. Mod Pathol 2014;27:631-639.
49.
Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A: The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 2015;21:1639-1651.
50.
Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G: Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol 2013;13:36.
51.
Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386-1394.
52.
Patel SP, Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847-856.
53.
Li GW, Xie XS: Central dogma at the single-molecule level in living cells. Nature 2011;475:308-315.
54.
Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK: Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009;459:428-432.
55.
Burga A, Casanueva MO, Lehner B: Predicting mutation outcome from early stochastic variation in genetic interaction partners. Nature 2011;480:250-253.
56.
Paek AL, Liu JC, Loewer A, Forrester WC, Lahav G: Cell-to-cell variation in p53 dynamics leads to fractional killing. Cell 2016;165:631-642.
57.
Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J: Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997;57:1597-1604.
58.
Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gurel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S: Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013;123:4918-4922.
59.
Comen EA: Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discov Med 2012;14:97-104.
60.
Turajlic S, Swanton C: Metastasis as an evolutionary process. Science 2016;352:169-175.
61.
Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF: Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014;15:454.
62.
Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li HY, Ren GS, Wu KN, Wang DL, Kong LQ: Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol 2014;31:798.
63.
Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, McCart Reed AE, Kutasovic JR, Morey AL, Marquart L, O'Rourke P, Lakhani SR: Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol 2014;232:23-31.
64.
Bonin S, Pracella D, Barbazza R, Sulfaro S, Stanta G: In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival. Virchows Arch 2015;466:571-580.
65.
Talmadge JE, Fidler IJ: AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010;70:5649-5669.
66.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Hognas G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, Group IPU, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS: The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353-357.
67.
Thirlwell C, Will OC, Domingo E, Graham TA, McDonald SA, Oukrif D, Jeffrey R, Gorman M, Rodriguez-Justo M, Chin-Aleong J, Clark SK, Novelli MR, Jankowski JA, Wright NA, Tomlinson IP, Leedham SJ: Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology 2010;138:1441-1454, 1454.e1-e7.
68.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
69.
Seufferlein T, Van Lint J, Liptay S, Adler G, Schmid RM: Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 1999;116:1441-1452.
70.
Yamamoto H, Imai K: Microsatellite instability: an update. Arch Toxicol 2015;89:899-921.
71.
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
72.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
73.
Briggs S, Tomlinson I: Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 2013;230:148-153.
74.
Muller MF, Ibrahim AE, Arends MJ: Molecular pathological classification of colorectal cancer. Virchows Arch 2016;469:125-134.
75.
van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, Smit VT, Nijman HW, Bosse T, Church DN: POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015;21:3347-3355.
76.
Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-130.
77.
Rashid A, Issa JP: CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 2004;127:1578-1588.
78.
Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H: Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics 2016;8:25.
79.
Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M: Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun 2014;455:35-42.
80.
Burrell RA, McGranahan N, Bartek J, Swanton C: The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-345.
81.
Santaguida S, Amon A: Short- and long-term effects of chromosome mis-segregation and aneuploidy. Nat Rev Mol Cell Biol 2015;16:473-485.
82.
Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE, Amon A: Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 2008;322:703-709.
83.
Donnelly N, Passerini V, Durrbaum M, Stingele S, Storchova Z: HSF1 deficiency and impaired HSP90-dependent protein folding are hallmarks of aneuploid human cells. EMBO J 2014;33:2374-2387.
84.
Tang YC, Williams BR, Siegel JJ, Amon A: Identification of aneuploidy-selective antiproliferation compounds. Cell 2011;144:499-512.
85.
Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, Murali R, Vickers A, Scardino PT, Sander C, Reuter V, Taylor BS, Sawyers CL: Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA 2014;111:11139-11144.
86.
Carethers JM, Koi M, Tseng-Rogenski SS: EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (Basel) 2015;6:185-205.
87.
Tseng-Rogenski SS, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM: Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS One 2012;7:e50616.
88.
Yamada K, Kanazawa S, Koike J, Sugiyama H, Xu C, Funahashi K, Boland CR, Koi M, Hemmi H: Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol Rep 2010;23:551-561.
89.
Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lonning PE, Wedge DC, Campbell PJ: Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 2015;21:751-759.
90.
Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, Nicol DL, Hazell S, Futreal PA, Stewart A, Swanton C: Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225-233.
91.
Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-1113.
92.
McBride M, Rida PC, Aneja R: Turning the headlights on novel cancer biomarkers: inspection of mechanics underlying intratumor heterogeneity. Mol Aspects Med 2015;45:3-13.
93.
Chan JY: A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 2011;7:1122-1144.
94.
Godinho SA, Pellman D: Causes and consequences of centrosome abnormalities in cancer. Philos Trans R Soc Lond B Biol Sci 2014;369:20130467.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
